Mirici, ArzuGonlugur, Ugur2025-01-272025-01-2720111305-2381https://hdl.handle.net/20.500.12428/24320Significant advances in the treatment of pulmonary arterial hypertension have occurred in the last decade. Over this same period, the classification of pulmonary hypertension has also been revised. The most important drugs in the therapy are calcium-channel antagonists, prostanoids, endothelin antagonists, and phosphodiesterase 5 inhibitors. The therapeutic option changes according to the New York Heart Association classification in such patients. The aim of this review is to describe the current state for the treatment of the patients with pulmonary arterial hypertension.trinfo:eu-repo/semantics/closedAccessPulmonary hypertensiontherapybosentansildenafililoprostArticle71511Q4WOS:000290003500002